IDEXX raises fiscal 2026 guidance as recurring diagnostics sales grow
IDEXX reported third-quarter revenue up 10% and recurring CAG Diagnostics revenue up 11%, prompting higher FY26 revenue and EPS guidance, per TradingView.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
IDEXX Laboratories reported third-quarter revenue up 10%. According to TradingView, recurring CAG Diagnostics revenue rose 11%, which led the company to lift its fiscal 2026 revenue and earnings-per-share guidance.
Visits to veterinary clinics remained under pressure, while practice revenue was positive.
why it matters
For investors, growth in recurring revenue is typically seen as more predictable than one-off sales. The higher full-year outlook supports the case for the shares, but weak clinic visits remain the main risk to the business.
market impact
IDEXX shares: higher guidance and recurring revenue growth support the stock
- IDEXX Laboratories shares pressure up — raised revenue and EPS guidance and growth in recurring sales
tags
instruments
sources
- IDXX: Recurring diagnostics growth lifted FY26 revenue and EPS guidance — TradingView, 2 November 2026 at 23:02 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗